Australia's Orthocell rises on regulatory nod to begin sales in Canada

Orthocell

30/04/2025 02:02

** Shares of Orthocell Ltd OCC.AX rise 3.8% to A$1.52, their highest since April 10

** The biotech firm receives regulatory approval from Health Canada to commence sales of its flagship nerve repair product Remplir in Canadian market

** Co says first sales expected in the second half of 2025

** Stock up 11.1% YTD, including moves in the current session

(Reporting by Jasmeen Ara Shaikh in Bengaluru)

((JasmeenAraIslam.Shaikh@thomsonreuters.com;))